Marker Therapeutics is trading 10.03% up at $1.53, amid continued speculative momentum with no confirmed fresh catalyst identified.
- It closed at $1.39 on August 21, 2026, following a volatile multi-session advance; the broader market is mixed to lower, offering no clear market-wide explanation.
- H.C. Wainwright reiterated its Buy rating and $10.00 price target on August 21, citing the planned lymphoma trial and expected 2026 clinical updates; that news predates today’s move. Confidence is low.